Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience-Reference-Cited by-同舟云学术

Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience

Published:2021-10 Issue: Volume:187 Page:106551
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Isshiki Takuma^ORCID,Sakamoto Susumu,Yamasaki Akira,Shimizu Hiroshige,Miyoshi Shion^ORCID,Nakamura Yasuhiko,Homma Sakae,Kishi Kazuma^ORCID

Funder

Ministry of Health, Labour and Welfare

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference28 articles.

1. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am. J. Respir. Crit. Care Med.,2011

2. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report;Collard;Am. J. Respir. Crit. Care Med.,2016

3. Clinical Diagnostic and Treatment Guidance for Idiopathic Interstitial Pneumonias;Japanese Respiratory Society’s Committee formulating diagnosis and treatment guideline for diffuse lung diseases,2011

4. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome;Song;Eur. Respir. J.,2011

5. IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials;Collard;Respir. Res.,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF);Expert Review of Clinical Pharmacology;2024-08-27

2. Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review;Frontiers in Medicine;2024-08-06

3. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-07-04

4. Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments;Journal of Thoracic Disease;2024-07

5. Mannosylated polydopamine nanoparticles alleviate radiation- induced pulmonary fibrosis by targeting M2 macrophages and inhibiting the TGF-β1/Smad3 signaling pathway;Colloids and Surfaces B: Biointerfaces;2023-07